AR and neoplasm: This would be consistent with GEMM studies demonstrating that tumors harboring alterations in all three tumor suppressors (Pten, Rb1, Tp53) have de novo resistance to AR-targeted therapy whereas the presence of only two of the three alterations requires an additional period of acquired resistance [51,52].